Circulating Proneurotensin Levels Predict Impaired Bone Mineralisation in Postmenopausal Women With Type 2 Diabetes Mellitus
Authors:
Open Access
- 10 December 2024
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (1) , e70018
Abstract
Context: The mechanisms underlying bone fragility and increased fracture risk observed in individuals with type 2 diabetes (T2D) are not yet fully elucidated. Previous research has suggested a role for neuropeptides in regulating bone metabolism; however, the contribution of the neuropeptide Neurotensin (NT), which is thoroughly implicated in T2D and cardiovascular disease, has not been investigated in this context.Objective: To study the relationship between circulating levels of the NT precursor proneurotensin (proNT) and bone mineralisation in T2D women.Materials and Methods: This is a cross‐sectional investigation with a longitudinal prospective phase, involving 126 women with T2D who underwent bone density scans and had proNT levels measured. Biomarkers of bone metabolism and inflammation were also assessed. Data on bone mineral density (BMD) after 12 months were available for 49 patients.Main Outcome Measure: Plasma proNT levels in relation to BMD.Results: 32% of the participants had osteopenia/osteoporosis and exhibited higher proNT than those with normal BMD (200.8 ± 113.7 vs. 161.6 ± 108.8 pg/mL; p = 0.013). ProNT inversely correlated with femur BMD and T‐score (p < 0.01) and was associated with degraded bone architecture (TBS, p = 0.02), and higher OPN, P1NP, TNF‐α and IL‐1β levels. Baseline proNT correlated with further BMD reduction at the 12‐month follow‐up, independently of potential confounders (p = 0.02).Conclusions: In women with T2D, greater proNT levels are associated with impaired bone mineralisation and predict mineral density decline overtime. ProNT could potentially serve as a diagnostic tool for identifying patients at higher risk of osteopenia/osteoporosis, suggesting a significant connection between this neuropeptide and bone metabolism in diabetes.Keywords
Funding Information
- Agenzia Italiana del Farmaco, Ministero della Salute
This publication has 35 references indexed in Scilit:
- Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of MetabolismEndocrinology, 2016
- Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort StudyJournal of Bone and Mineral Research, 2015
- Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosisJournal of Clinical Investigation, 2014
- Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and MortalityJAMA, 2012
- Mast cells and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptorsNeuropeptides, 2007
- Proneurotensin 1–117, a stable neurotensin precursor fragment identified in human circulationPeptides, 2006
- Immunoreactive Neurotensin in Gonadotrophs and Thyrotrophs is Regulated by Sex Steroid Hormones in the Female RatJournal of Neuroendocrinology, 1999
- The Regulation of Neuropeptide Expression in Rat Anterior Pituitary following Chronic Manipulation of Estrogen Status: A Comparison between Substance P, Neuropeptide Y, Neurotensin, and Vasoactive Intestinal PeptideEndocrinology, 1990
- Neurotensin modulates human neutrophil locomotion and phagocytic capabilityFEBS Letters, 1983